Chimerism and clinical course
| Patient . | Donor-specific cells in . | Rejection episodes . | Current immunosuppressive therapy . | |
|---|---|---|---|---|
| CD34+ cells . | PB . | |||
| 1 | Pos. | Pos. | 0 | CycloA |
| 2 | Pos. | Pos. | 3 | FK506 |
| 3 | Pos. | Pos. | 2 | FK506 |
| 4 | Pos. | Neg. | 2 | CycloA |
| 5 | Pos. | Neg. | 5 | CycloA |
| 6 | Neg. | Pos. | 3 | CycloA + MP |
| 7 | Neg. | Pos. | 3 | FK506 + MP |
| 8 | Neg. | Neg. | 3 | CycloA + MP |
| 9 | Pos. | Pos. | 1 | FK506 + MP |
| 10 | Neg. | Neg. | 0 | FK506 + MP |
| 11 | Neg. | Neg. | 2 | CycloA + MP |
| 12 | not evaluable | not evaluable | 0 | CycloA + MP |
| Patient . | Donor-specific cells in . | Rejection episodes . | Current immunosuppressive therapy . | |
|---|---|---|---|---|
| CD34+ cells . | PB . | |||
| 1 | Pos. | Pos. | 0 | CycloA |
| 2 | Pos. | Pos. | 3 | FK506 |
| 3 | Pos. | Pos. | 2 | FK506 |
| 4 | Pos. | Neg. | 2 | CycloA |
| 5 | Pos. | Neg. | 5 | CycloA |
| 6 | Neg. | Pos. | 3 | CycloA + MP |
| 7 | Neg. | Pos. | 3 | FK506 + MP |
| 8 | Neg. | Neg. | 3 | CycloA + MP |
| 9 | Pos. | Pos. | 1 | FK506 + MP |
| 10 | Neg. | Neg. | 0 | FK506 + MP |
| 11 | Neg. | Neg. | 2 | CycloA + MP |
| 12 | not evaluable | not evaluable | 0 | CycloA + MP |
CycloA indicates cyclosporine A; FK506, tacrolimus; MP, methylprednisolone; PB, peripheral blood.